Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'

An analyst is initiating a 'buy' rating for Doximity (DOCS), setting a fair value of $62 per share, citing its strong network effects within the healthcare professional community (80% of US physicians) and its significant growth potential in the pharmaceutical marketing and workflow solutions markets. Doximity's Q4 FY25 results showed 17% revenue growth and 24% adj. EBITDA growth, with the company projecting $619-$631 million in revenue for FY26; however, high stock-based compensation and competition from companies like Teladoc Health pose potential risks to future growth and margin expansion.

Analysis

Doximity (NYSE:DOCS) is presented with a 'buy' rating and a $62 per share fair value, underpinned by its dominant network encompassing 80% of U.S. physicians, which functions as a "LinkedIn for healthcare professionals." The company has demonstrated robust financial traction, achieving 32% revenue and 52% adjusted EBITDA CAGR from 2020 to 2025, with Q4 FY25 results showing 17% revenue growth and 24% adjusted EBITDA year-over-year growth. Management's guidance for FY26 projects revenue between $619-$631 million and adjusted EBITDA of $333-$345 million. Doximity's growth is fueled by its strong position in pharmaceutical marketing, where it outpaces market growth twofold, and significant expansion opportunities within an $18.5 billion total addressable market, especially among small and medium-sized pharma brands where current penetration is low (11%). The company also plans to expand its healthcare marketing/staffing and telehealth services, with its workflow solutions already engaging over 620,000 unique active prescribers. Financially, Doximity maintains a debt-free balance sheet and has actively repurchased $486 million of its shares over the past three years, supported by strong free cash flow. Projections anticipate 15% annual revenue growth, driven by a net revenue retention rate near 120%. However, key risks include substantial stock-based compensation, which totaled $72 million (12.7% of revenue) in FY25, potentially hindering margin expansion despite forecasts of a 20bps operating margin increase. Furthermore, challenging macroeconomic conditions could affect SMB pharma clients, and Doximity faces notable competition in the telehealth market from established players like Teladoc Health (TDOC).

Key Decisions for Investors

• Investors should consider the 'buy' rating and $62 fair value, recognizing Doximity's strong network effects, consistent double-digit revenue growth (e.g., 17% in Q4 FY25), and substantial untapped market in pharmaceutical marketing, particularly with SMBs.
• Vigilance is required regarding Doximity's high stock-based compensation (12.7% of FY25 revenue), as this could pressure margin expansion despite positive operating leverage and customer retention contributing to a projected 20bps margin increase.
• Monitor Doximity's strategic responses to competitive pressures in the telehealth sector from dedicated providers like Teladoc Health, as market share gains may necessitate further investment or acquisitions.
• Assess the ongoing impact of the broader economic environment and interest rates on Doximity's SMB pharma clients, as this segment's performance is critical to achieving the guided 15% annual revenue growth.